IMMUNOVANT, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.17 USD | -2.09% |
|
-3.72% | -35.51% |
| Apr. 20 | Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing | MT |
| Apr. 20 | Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing | MT |
Valuation
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 850.7 | 1,571 | 641.3 | 2,005 | 3,948 | - | - |
| Enterprise Value (EV) 1 | 850.7 | 1,171 | 147.5 | 1,628 | 3,295 | 3,416 | 3,660 |
| P/E ratio | -10.1 x | -13.1 x | -3.85 x | -9.07 x | -15.2 x | -14.9 x | -13.8 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | 274 x | 75.4 x |
| EV / Revenue | - | - | - | - | - | 237 x | 69.9 x |
| EV / EBITDA | - | -10.8 x | -0.95 x | -7.47 x | -12.7 x | -13.2 x | -11.9 x |
| EV / FCF | -15.9 x | -14 x | -1.39 x | -8.64 x | -15.6 x | -12.2 x | -13.4 x |
| FCF Yield | -6.28% | -7.13% | -72.1% | -11.6% | -6.4% | -8.23% | -7.48% |
| Price to Book | - | 3.6 x | 1.29 x | 5.58 x | 6.03 x | 9.68 x | 25.3 x |
| Nbr of stocks (in thousands) | 54,655 | 97,971 | 116,396 | 129,260 | 145,293 | - | - |
| Reference price 2 | 15.56 | 16.04 | 5.510 | 15.51 | 27.17 | 27.17 | 27.17 |
| Announcement Date | 6/29/20 | 6/1/21 | 6/8/22 | 5/22/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 14.41 | 52.37 |
| EBITDA 1 | - | -108.1 | -155.9 | -218.1 | -259.4 | -259.5 | -307.9 |
| EBIT 1 | -66.08 | -108.1 | -156 | -218.3 | -266.4 | -291.2 | -319.7 |
| Operating Margin | - | - | - | - | - | -2,020.6% | -610.55% |
| Earnings before Tax (EBT) 1 | -66.29 | -107.8 | -156.8 | -211 | -251.6 | -300.5 | -314.1 |
| Net income 1 | -66.39 | -107.4 | -156.7 | -211 | -249.6 | -275.7 | -313.2 |
| Net margin | - | - | - | - | - | -1,912.79% | -598.18% |
| EPS 2 | -1.540 | -1.220 | -1.430 | -1.710 | -1.787 | -1.825 | -1.976 |
| Free Cash Flow 1 | -53.39 | -83.54 | -106.4 | -188.4 | -211 | -281.1 | -273.7 |
| FCF margin | - | - | - | - | - | -1,950.27% | -522.61% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 6/29/20 | 6/1/21 | 6/8/22 | 5/22/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | -47.19 | -40.33 | -49.57 | -63.98 | -64.2 | -78.42 | -61.74 | -61.44 | -63.48 | - | - | - | - |
| EBIT 1 | -37.65 | -41.27 | -47.23 | -40.38 | -49.61 | -64.03 | -64.26 | -78.48 | -61.8 | -61.55 | -64.73 | -68.85 | -73.08 | -75.83 | -78.48 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -37.73 | -41.38 | -47.18 | -40.02 | -47.67 | -62.84 | -60.42 | -73.95 | -58.21 | -51.53 | -65.17 | -66.57 | -68.43 | -70.42 | -76.4 |
| Net income 1 | -37.7 | -41.38 | -47.17 | -40.37 | -47.93 | -63.23 | -59.43 | -73.94 | -58.66 | -51.42 | -63.04 | -65.28 | -67.62 | -70.35 | -75.82 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.3500 | -0.3600 | -0.4100 | -0.3500 | -0.4100 | -0.4900 | -0.4600 | -0.5700 | -0.4500 | -0.3600 | -0.4370 | -0.4450 | -0.4550 | -0.4762 | -0.5062 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/5/21 | 2/4/22 | 6/8/22 | 8/5/22 | 11/4/22 | 2/3/23 | 5/22/23 | 8/10/23 | 11/9/23 | 2/12/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 400 | 494 | 377 | 653 | 532 | 288 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -53.4 | -83.5 | -106 | -188 | -211 | -281 | -274 |
| ROE (net income / shareholders' equity) | - | -44.3% | -36.4% | -50.7% | -48.6% | -46.7% | -61% |
| ROA (Net income/ Total Assets) | - | - | - | - | -45.7% | -44.6% | - |
| Assets 1 | - | - | - | - | 546.2 | 618.1 | - |
| Book Value Per Share 2 | - | 4.460 | 4.280 | 2.780 | 4.510 | 2.810 | 1.070 |
| Cash Flow per Share 2 | - | -0.9500 | -0.9700 | -1.530 | -1.190 | -0.2700 | - |
| Capex 1 | 0.03 | 0.21 | 0.25 | 0.2 | 3.5 | 3.28 | 4.38 |
| Capex / Sales | - | - | - | - | - | 22.72% | 8.37% |
| Announcement Date | 6/29/20 | 6/1/21 | 6/8/22 | 5/22/23 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
27.17
USD
Average target price
50.43
USD
Spread / Average Target
+85.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -35.51% | 3.95B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- IMVT Stock
- Financials Immunovant, Inc.
